Continuous renal replacement therapy (CRRT) market is anticipated to grow at a CAGR of 5.8% during the forecast period (2024-2031). CRRT is a form of dialysis treatment commonly utilized in critically ill patients suffering from acute kidney injury (AKI). The therapy is administered continuously for 24 hours to offer renal support in intensive care units (ICUs). The pivotal factors driving the industry growth include the growing prevalence of AKI, chronic diseases such as diabetes, significant advancements in technology such as improved monitoring systems and better filtration technologies, increasing expenditure on healthcare infrastructure, regulatory support policies, an aging population, and growth in early diagnostic awareness.

Market Dynamics  

Increasing Prevalence of Acute Kidney Injury (AKI)

The global healthcare sector is recording an immense growth in acute kidney injuries attributed to the constant increase in the number of chronic disease (diabetes, hypertension) patients. The rise in the prevalence of severe disease across a larger section of the population has influenced both the current number of AKI patients as well as the future risk of grasping similar diseases, which has collectively benefited the CRRT diagnosis market. For instance, the National Diabetes Statistics Report 2021 indicates that 38.4 million individuals in the U.S. have diabetes, which accounts for 11.6% of the population. Among this number, 29.7 million have been diagnosed, including 29.4 million adults. Furthermore, 8.7 million individuals with diabetes remain undiagnosed, constituting 22.8% of the affected adults. Uncontrolled diabetes can damage the kidneys, leading to a condition called diabetic nephropathy. Around 40% of people with diabetes could eventually develop diabetic kidney disease, which is also known as diabetic nephropathy.

Additionally, according to the World Health Organization (WHO), approximately 1.28 billion adults aged 30-79 worldwide suffer from hypertension, with the majority residing in low- and middle-income countries. An estimated 46% of adults with hypertension are unaware of their condition. Diagnosis and treatment are received by less than half of adults (42%) with hypertension. Lastly, only 21% of adults with hypertension have it under control. High blood pressure is the second leading cause of kidney failure in the US after diabetes. 

Causes of Kidney Failure in the US (%)

Source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Advancement in CRRT Diagnosis Technology

Simultaneously, as the prevalence of AKI and related diseases is increasing, major companies in the market are concentrating on developing novel technology that can facilitate better treatment for the disease. The advancement includes a wide range of upgrades and integrations, such as the use of advanced monitoring and automation, integration with electronic health records (EHRS), enhanced biocompatibility, and membrane technology, among others. For instance, in March 2024, Fresenius Medical Care (FME), the provider of CRRT products and services, introduced a new "Augmented Reality" (AR) application designed to facilitate learning for nursing staff involved in kidney replacement therapy in intensive care units. The AR glasses, when used alongside digital learning modules, enable nursing staff to receive training on how to operate acute dialysis machines directly in the intensive care units. The glasses provide visual and auditory feedback as users interact with the dialysis machine, offering a fully immersive learning experience to healthcare professionals.

Segmental Outlook 

• Based on product, the market is segmented into dialysates and replacement fluids, disposables, hemofilters, bloodline sets & tubes, and other disposables.

• Based on modality, the market is segmented into Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodiafiltration (CVVHDF), Continuous Venovenous Haemodialysis (CVVHD), and Slow Continuous Ultrafiltration (SCUF).

• Based on age group, the market is segmented into adults, and pediatrics /neonates.

Continuous Venovenous Hemodiafiltration (CVVHDF) is the Most Prominent CRRT Modality

CVVHDF is a highly preferred modality type in CRRT owing to its efficacy in eliminating solutes and fluids from the blood, making it suitable for AKI patients. It combines the benefits of hemodialysis and hemofiltration, ensuring efficient removal of middle and large molecular weight toxins while preserving hemodynamic stability. The increasing utilization of CVVHDF in critical care protocols is driven by its potential to enhance patient outcomes and lessen mortality linked to severe kidney conditions as healthcare systems progress.

Adults are the Biggest Age-Group Segment

The adult population dominates treatment consumption for CRRT owing to the higher risk of chronic diseases in the aging population, the lower level of immunity resistance to diseases, and the incremental impacts of multiple diseases in the adult population. For instance, according to National Council of Aging (NCOA) research, nearly 95% of adults 60 and older have at least one chronic condition, while nearly 80% have two or more.

Regional Outlook 

The global continuous renal replacement therapy market is further segmented based on geography including North America (the US, and Canada), Europe (the UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).  

North America Holds Significant Market in Continuous Renal Replacement Therapy Market

North America is predicted to demonstrate the highest growth rate in the future, attributed to the ongoing increase in healthcare expenditure made by regional governments, the rising prevalence of chronic diseases, particularly in young populations, the presence of major CRRT product manufacturers such as Baxter and Medtronic, among others, growing R&D investment in chronic disease treatment and product development, the expansion of the aging population, and a supportive regulatory framework. For instance, in September 2023, Quanta Dialysis Technologies announced its acquittal of regulatory clearance from the US Food and Drug Administration (FDA) for an expanded indication of the Quanta Dialysis System. This compact and user-friendly hemodialysis device is now cleared for two modalities of CRRT, which are CVVHD and SCUF. With this new 510(k) clearance, the Quanta Dialysis System stands out as the only dialysis device approved by the FDA to offer intermittent hemodialysis (IHD), sustained low-efficiency dialysis (SLED), and bagless CRRT, which generates dialysate on demand—all within a single machine.

Global Continuous Renal Replacement Therapy (CRRT) Market Growth by Region 2024-2031

Asia-pacific is the Fastest Growing in Continuous Renal Replacement Therapy Industry

• Asia-Pacific is one of the most highly exposed regions for the prevalence of chronic diseases such as diabetes, hypertension, and AKI. 

• Asian countries have been consistently invested in developing, upgrading, and modernizing healthcare infrastructure. Further, the countries also export a vast amount of equipment and pharmaceuticals for severe diseases to western regions, showcasing the regional capabilities for product development in the future.

Market Players Outlook 

*Note: Major Players Sorted in No Particular Order. 

The major companies serving the global continuous renal replacement therapy (CRRT) market include Baxter International Inc., Fresenius Medical Care AG & CO. KGaA, and Medtronic PLC, among others. The market players are focusing on capitalizing on growth by adopting strategies such as collaboration, partnerships, and market expansion among others. For instance, in January 2023, Baxter International Inc., a global MedTech company unveiled a comprehensive strategic plan aimed at significantly improving its operational efficiency, driving towards better long-term performance, hastening innovation, and generating added value for all stakeholders. These initiatives encompass the decision to separate the company's Renal Care and Acute Therapies global business units (GBUs) into an independent, publicly traded entity; streamlining commercial and manufacturing operations to boost the fundamental business performance; and undertaking additional portfolio measures to enhance Baxter's capital structure, including a review of strategic options for the BioPharma Solutions (BPS) business.

The Report Covers 

• Market value data analysis of 2023 and forecast to 2031. 
• Annualized market revenues ($ million) for each market segment. 
• Country-wise analysis of major geographical regions. 
• Key companies operating in the global continuous renal replacement therapy (CRRT) market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. 
• Analysis of market-entry and market expansion strategies. 
• Competitive strategies by identifying ‘who-stands-where’ in the market.